APA (7th ed.) Citation

A, N., A, A., A, S., W, M., J, T., V, K., . . . Y, S. (2021). Belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma in heavily pretreated patients: A US cost-effectiveness analysis. Expert review of hematology, 14(12), 1137. https://doi.org/10.1080/17474086.2021.1970522

Chicago Style (17th ed.) Citation

A, Nikolaou, et al. "Belantamab Mafodotin for the Treatment of Relapsed/refractory Multiple Myeloma in Heavily Pretreated Patients: A US Cost-effectiveness Analysis." Expert Review of Hematology 14, no. 12 (2021): 1137. https://doi.org/10.1080/17474086.2021.1970522.

MLA (9th ed.) Citation

A, Nikolaou, et al. "Belantamab Mafodotin for the Treatment of Relapsed/refractory Multiple Myeloma in Heavily Pretreated Patients: A US Cost-effectiveness Analysis." Expert Review of Hematology, vol. 14, no. 12, 2021, p. 1137, https://doi.org/10.1080/17474086.2021.1970522.